Merck

Anti-malarial activity of N6-modified purine analogues.

Bioorganic & medicinal chemistry (2007-06-06)
Kathleen Too, Daniel M Brown, Emily Bongard, Vanessa Yardley, Livia Vivas, David Loakes
ABSTRACT

Plasmodium falciparum causes one of the deadliest forms of malaria and resistance to the currently available drugs makes it imperative to develop new, safe and potent drugs. Parasites such as P. falciparum are unable to synthesise purines de novo and to this end often have multiple purine uptake and salvage systems. With this in mind, we have designed and synthesised libraries of purine analogues as potential anti-malarial agents. Herein, we report three compounds with promising activity against the highly chloroquine-resistant VS1 P. falciparum namely: N(6)-hydroxyadenine (1c), 2-amino-N(6)-aminoadenosine (2b) and 2-amino-N(6)-amino-N(6)-methyladenosine (4b).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Podophyllotoxin